Active ingredientLumacaftorCat. No. P-L106-001CAS 936727-05-8Family · Pharmaceutical analytical standards
Lumacaftor
A CFTR protein corrector: it helps the faulty F508del protein to be processed correctly and reach the cell surface. In combination with ivacaftor it was approved in the United States in July 2015 for cystic fibrosis. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?It was the first treatment approved for people with two copies of the F508del mutation, a condition shared by about half of the people with cystic fibrosis in the United States.
Go to the active ingredient →Active ingredientLumacaftorCat. No. P-L106-001CAS 936727-05-8
MetaboliteLumacaftor GlucuronideCat. No. P-L106-002
Isotopically labelledLumacaftor-d4Cat. No. P-L106-003CAS 2733561-44-7
ImpurityLumacaftor Impurity 1Cat. No. P-L106-004
ImpurityLumacaftor Impurity 2Cat. No. P-L106-005
ImpurityLumacaftor Impurity 3Cat. No. P-L106-006CAS 2732521-08-1No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.